Haemophilia treatment hits unexpected setback
This article was originally published in Scrip
Executive Summary
The US FDA has placed a hold on two Phase III trials of IB1001, Ipsen and Inspiration Biopharmaceuticals' intravenous recombinant factor IX for the treatment and prevention of bleeding episodes in people with haemophilia B.